Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Point72 | Vintage Vibes

Major Wall Street firms targeted in attempted cyberattacks, sources say

Major Wall Street financial firms faced sophisticated cyberattacks recently. Hackers used phone calls to trick employees into granting access. Several large hedge funds and private equity firms were targeted by these attempts. Point72 Asset Management confirmed an attack but stated no customer data was stolen. Global companies are now battling…

The Economic Times

Steve Cohen's Point72 Boosts Stake in Beaten-Down Biotech Stock by 5,100% Despite Disappointing Trial Results

Billionaire Steve Cohen still backs biotech Evommune despite trial setbacks, highlighting its potential for treating chronic conditions and its strategic role in his portfolio.

International Business Times UK

Steve Cohen's Point72 Buys $20M of Biotech Stock Advancing Depression Treatment

Point72 Asset Management purchased over 1.2 million shares of Tonix Pharma at $16.28 each as the company aggressively advances its drug development programmes.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Steve Cohen's Point72 Buys $156M Worth of Bill Holdings Shares Ahead of Potential Sale

Point72 increased its stake in Bill Holdings by over 180% amid rumours of a potential sale, as the cloud software firm faces declining revenues and stiff sector competition.

International Business Times UK

Mets Owner Steve Cohen Makes $64M Bet on Lionsgate Studios Just Days Before Earnings—Stepping Up Stake by 220%

Billionaire Mets owner Steve Cohen's hedge fund, Point72, acquired over 10 million shares of Lionsgate Studios for $64 million just days before the company's fiscal Q2 earnings on 6th November.

International Business Times UK

Steve Cohen's Point72 Buys $20M of Surging Biotech Stock That Recently Priced $125M Offering to Advance Myeloma Treatment

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data of a drug to treat myeloma and raised $125 million to fund upcoming trials.

International Business Times UK

Cohen's Point72 Pours $14M in This Biotech Stock That Gained 250% in a Month, and Recently Raised $138M in Funding

Steve Cohen's Point72 Asset Management added Palisade Bio to the hedge fund's portfolio amid the company's announcement of positive phase 1 trial data and funding to advance phase 2 trials.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut

Steven Cohen's Point72 Asset Management just pulled off what most fund managers only dream of — doubling the SP 500's three-year return — and he's still not easing up. The billionaire investor's next move? A fresh swing into biotech, backing Palisade Bio Inc (NASDAQ:PALI) — a tiny, high-volatility stock working…

Benzinga

Here's Why Point72's Steve Cohen's Bought Millions Worth of Biotech Stocks Last Week

New York Mets owner and billionaire investor Steve Cohen purchased two biotech stocks last week, one being a new addition to Point 72's portfolio.

International Business Times UK

Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller

Steven Cohen isn't afraid of volatility — and his latest moves show he's diving headfirst into small-cap biotech. The billionaire hedge fund manager's Point72 Asset Management has built new stakes in two clinical-stage companies, betting that their breakthroughs in genetic and antibody therapies could deliver outsized returns.

Benzinga

Steve Cohen's Point72 Goes Heavy on Tech and Pharma Stocks, Investing Over $330M in Two Trades

Point72 Asset Management recently purchased over 10 million shares of Confluent and Amylyx Pharma common stock, worth more than $334.17 million.

International Business Times UK

Here's Why Steve Cohen's Point72 Recently Shelled Out Over $100M for Two Biopharma Stocks

Billionaire investor Steve Cohen invested over $100 million in two biopharma stocks, one of which has rallied over 90% in the past one month.

International Business Times UK

Point72's Steve Cohen Adds $2B Worth of New Tech, Telco, and Healthcare Stocks in Q4

Billionaire investor Steven A. Cohen opened new stock positions, including Amazon, AT&T, Netflix, Salesforce, and UnitedHealth Group in Q4.

International Business Times UK

Billionaire hedge fund exec and Mets owner Steve Cohen says the key to success is to never stop working

The best traders are just like the best baseball players: “They can’t wait to work, even in the offseason.”

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Steve Cohen's Point72 to Raise $1 Billion for Launching AI-focused Hedge Fund

Steve Cohen recently revealed he is bullish on AI and believes it can significantly improve productivity in companies across industries.

International Business Times UK

Steve Cohen's Point72 Ups Stake in Boeing by Over 400% in Q1, Opens New Position in Broadcom

Boeing has trimmed delivery and production of its 737 Max fleet, while Broadcom's quarterly revenue jumped 34% YoY on high chip demand for AI data centres.

Zenger

For Mets Owner Steve Cohen NYC Casino Ambitions Part Of A Diversification Strategy

For Mets Owner Steve Cohen, NYC Casino Ambitions Are Part Of A Diversification Strategy

Zenger

For Mets Owner Steve Cohen Has NYC Casino Ambitions Part Of A Diversification Strategy

For Mets Owner Steve Cohen, NYC Casino Ambitions Are Part Of A Diversification Strategy

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Stock Picks That Billionaires Love

Billionaire investors are scooping up tech stocks, whether they're on sale or riding the AI wave.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.